Skip to main content

The CONCLUDE trial

The CONCLUDE trial addresses an important knowledge gap, providing head-to-head data for two long-acting insulin analogs – insulin degludec and insulin glargine 300. The insulins will be tested in people with type 2 diabetes that is poorly controlled on basal insulin with or without oral diabetes medications.

CONCLUDE trial results published: Similar rates of symptomatic hypoglycemia reported

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).

Read the interview transcript

Results from the CONCLUDE trial were presented at the 55th EASD Annual Meeting (EASD 2019):

CONCLUDE: A trial COmparing the efficacy aNd safety of insulin degLUDEc and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin and oral antidiabetic drugs 
Thursday, September 19, 12:00–13:00. Joslin Hall, Fira Barcelona Gran Via, Spain 
Session Chair: T. Heise, Germany

  1. Rationale, trial design and methods. T. R. Pieber, Austria
  2. Results. A. Philis-Tsimikas, USA
  3. Commentary. S. Del Prato, Italy

Back to the EASD 2019 conference hub